Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

22,549 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S, Kim C, Wolmark N. Paik S, et al. N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440. N Engl J Med. 2008. PMID: 18367751 No abstract available.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Perez EA, et al. Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19. Breast Cancer Res Treat. 2013. PMID: 23420271 Free PMC article.
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Pogue-Geile KL, et al. J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21. J Natl Cancer Inst. 2013. PMID: 24262440 Free PMC article. Clinical Trial.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. Paik S, et al. N Engl J Med. 2004 Dec 30;351(27):2817-26. doi: 10.1056/NEJMoa041588. Epub 2004 Dec 10. N Engl J Med. 2004. PMID: 15591335 Clinical Trial.
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S. Kim C, et al. J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26. J Clin Oncol. 2011. PMID: 21947828 Free PMC article.
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, Wolmark N, Kidwell K, Paik S, Swain SM. Yang SX, et al. J Clin Oncol. 2010 Jun 20;28(18):2974-81. doi: 10.1200/JCO.2009.26.1602. Epub 2010 May 17. J Clin Oncol. 2010. PMID: 20479407 Free PMC article. Clinical Trial.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Paik S, et al. J Clin Oncol. 2006 Aug 10;24(23):3726-34. doi: 10.1200/JCO.2005.04.7985. Epub 2006 May 23. J Clin Oncol. 2006. PMID: 16720680
Gene-expression-based prognostic assays for breast cancer.
Kim C, Paik S. Kim C, et al. Nat Rev Clin Oncol. 2010 Jun;7(6):340-7. doi: 10.1038/nrclinonc.2010.61. Epub 2010 May 4. Nat Rev Clin Oncol. 2010. PMID: 20440284 Review.
Cytoplasmic estrogen receptor in breast cancer.
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Welsh AW, et al. Clin Cancer Res. 2012 Jan 1;18(1):118-26. doi: 10.1158/1078-0432.CCR-11-1236. Epub 2011 Oct 6. Clin Cancer Res. 2012. PMID: 21980134 Free PMC article.
22,549 results
Jump to page